Development of sarcoidosis during anti-TNF-alpha treatment: what is the mechanism?
Shin
J I
JI
Kim
D S
DS
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects; D006801:Humans; D012507:Sarcoidosis / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha